Darovasertib Combo Hits PFS Endpoint in Uveal Melanoma

What happened

IDEAYA and Servier reported that the darovasertib combination achieved a statistically significant and clinically meaningful improvement in median progression-free survival (6.9 months vs. investigator's choice) in first-line HLA-A2*01-negative metastatic uveal melanoma, presented as a late-breaking oral at ASCO. This is the first registrational readout for darovasertib and validates the synthetic-lethality approach in a biomarker-defined population. However, the press release does not disclose the comparator arm's exact PFS, hazard ratio, or overall survival data, leaving key questions about the magnitude and durability of benefit. The trial (OptimUM-02) is phase 2/3, and the company likely aims for accelerated approval, but full details remain unknown until the ASCO presentation. The stock rose after the announcement, reflecting optimism, but the binary risk of eventual OS data and regulatory scrutiny persists.

Implication

The darovasertib PFS win is a significant milestone that validates the drug's efficacy and supports a path toward accelerated approval in HLA-A2*01-negative mUM, a niche with no approved therapies. However, the stock already trades at ~$34, nearly 3x cash, pricing in substantial success. Investors should await the full ASCO abstract and subsequent OS readouts to assess the breadth of the benefit; a modest PFS gain without OS improvement may limit commercial upside. The trial's comparator arm choice and the company's ability to replicate results in broader populations (e.g., neoadjuvant setting) remain key. Partner Servier's ex-US execution and potential milestone payments add upside optionality, but the GSK and Amgen partner exits temper enthusiasm. Overall, the data is a positive step but not a thesis-changer; the margin of safety remains thin given the pre-revenue status and ongoing R&D burn.

Thesis delta

The WAIT stance is now supported by tangible positive data, but not enough to upgrade to BUY. The darovasertib PFS result reduces the probability of a catastrophic failure, but OS data, regulatory interactions, and pipeline execution (IDE397, ADC programs) still need to de-risk further. The risk/reward has improved modestly, but the stock's valuation leaves little room for error, so we continue to wait for a more attractive entry or confirmatory OS readout before shifting stance.